Spruce Biosciences, Inc

Spruce Biosciences, Inc(SPRB)價格預測

$42.710

-3.575 (-8.37%)收盤時

價格預測

1-Day Price Prediction
-1.00%
1-Week Prediction
-1.38%
1-Month Prediction
—
2026 Prediction
—
2030 Prediction
—

在 App 中開啟以解鎖更長週期的預測。

Loading chart…

SPRB 相似圖表分析預測

Alphio's SPRB stock price prediction model matches the current Spruce Biosciences, Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $42.28 (-1.00%). The 1-week path is $42.12 (-1.38%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

該買進 Spruce Biosciences, Inc 股票嗎?

Spruce Biosciences Inc (SPRB) is a good buy right now, trading at $44.55, significantly below its 52-week high of $129. The stock has a forward P/E of 0, indicating potential for future earnings growth as it develops its lead asset, TA-ERT, which has received favorable designations from the FDA. Analysts project a price target of $149, suggesting a potential upside of over 335% from the current price. However, the company reported a disappointing Q1 EPS of -$8.94, which missed expectations and reflects ongoing profitability challenges, presenting a risk to investors.

SPRB 股價於 Thursday 收在 $42.71,此前下跌 -8.37%

Spruce Biosciences, Inc (SPRB) last closed at $42.7099991, losing -8.37%. These facts feed the 1-day and 1-week SPRB price prediction above.

預測驅動因素

Spruce Biosciences, Inc(SPRB)的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。

Similar patterns

Positive

Bullish

Seasonality

Negative

Bearish

SMA 20

Negative

Bearish

SMA 200

Negative

Bearish

相似圖表形態

近期走勢與 SPRB 最接近的股票,依相似度排序。

SPRB 季節性分析

Historically the probability of a positive November return for SPRB is 44.19%. December offers the highest probability of a positive month at 51.16%, while April is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.

Loading chart…

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易